Senseonics Holdings, Inc. (NASDAQ:SENS – Get Free Report) was down 6.4% during mid-day trading on Thursday. The stock traded as low as $9.10 and last traded at $9.1150. Approximately 582,988 shares changed hands during mid-day trading, a decline of 18% from the average daily volume of 707,141 shares. The stock had previously closed at $9.74.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on the company. Mizuho raised their target price on Senseonics from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, November 10th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $10.00 price objective (up from $9.00) on shares of Senseonics in a research report on Tuesday, November 10th. Barclays lifted their price objective on shares of Senseonics from $10.00 to $11.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 10th. Wall Street Zen raised shares of Senseonics from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Finally, Weiss Ratings upgraded shares of Senseonics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $14.40.
Read Our Latest Research Report on Senseonics
Senseonics Stock Performance
The company has a debt-to-equity ratio of 0.70, a current ratio of 5.92 and a quick ratio of 5.60. The stock has a market capitalization of $484.37 million, a P/E ratio of -3.85 and a beta of 1.04. The company has a fifty day moving average of $9.23 and a two-hundred day moving average of $7.37.
Senseonics (NASDAQ:SENS – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). Senseonics had a negative return on equity of 186.11% and a negative net margin of 204.01%. The business had revenue of $19.56 million during the quarter. On average, equities analysts anticipate that Senseonics Holdings, Inc. will post -2.20 EPS for the current year.
Insider Activity at Senseonics
In other news, Director Douglas Roeder acquired 17,041 shares of the company’s stock in a transaction dated Friday, November 13th. The shares were bought at an average price of $10.32 per share, with a total value of $175,863.12. Following the purchase, the director owned 189,712 shares of the company’s stock, valued at approximately $1,957,827.84. This represents a 9.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.70% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Senseonics
A number of institutional investors and hedge funds have recently modified their holdings of SENS. Bank of America Corp DE acquired a new stake in shares of Senseonics in the second quarter worth $2,241,000. BlackRock Inc. purchased a new position in shares of Senseonics during the second quarter valued at $15,867,000. Masters Capital Management LLC raised its position in Senseonics by 100.0% during the first quarter. Masters Capital Management LLC now owns 500,000 shares of the company’s stock valued at $3,330,000 after buying an additional 250,002 shares during the period. Readystate Asset Management LP acquired a new position in Senseonics during the second quarter valued at $574,000. Finally, Penn Capital Management Company LLC acquired a new position in Senseonics during the second quarter valued at $535,000. 12.36% of the stock is owned by institutional investors and hedge funds.
About Senseonics
Senseonics Holdings, Inc. develops continuous glucose monitoring (CGM) technology for people with diabetes. Its Eversense systems use a small sensor implanted under the skin to measure glucose levels, an external wearable transmitter to send readings, and a mobile app to display data and provide alerts. The company’s product line includes implantable CGM systems designed for extended wear, including the Eversense 365 system, which is designed to last up to one year. Unlike many CGM products that use sensors replaced more frequently, Eversense sensors are inserted and removed by a healthcare professional.
See Also
- Five stocks we like better than Senseonics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.
